TTC

(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE

Find entries where: TTC

is present as a standalone ligand in 5 entries

as a non-polymer is covalently linked to polymer or other heterogen groups 1 entries

Find related ligands:

Chemical Component Summary
Name	(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
Synonyms	TOPOTECAN, HYCAMTIN
Identifiers	n/a
Formula	C₂₃ H₂₃ N₃ O₅
Molecular Weight	421.45
Type	NON-POLYMER
Isomeric SMILES	CC[C@@]1(C2=C(COC1=O)C(=O)N3Cc4cc5c(ccc(c5CN(C)C)O)nc4C3=C2)O
InChI	InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
InChIKey	UCFGDBYHRUNTLO-QHCPKHFHSA-N

Chemical Details
Formal Charge	0
Atom Count	54
Chiral Atom Count	1
Bond Count	58
Aromatic Bond Count	18

Drug Info: DrugBank

DrugBank ID	DB01030
Name	Topotecan
Groups	approved investigational
Description	An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Synonyms	Topotecanum Topotecan Topotecane Topotecan hydrochloride 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
Brand Names	Hycamtin Topotecan for Injection PMS-topotecan Topotecan Hospira Mylan-topotecan Hydrochloride for Injection Topotecan Topotecan hydrochloride Topotecan Hydrochloride for Injection Topotecan Hydrochloride Potactasol Topotecan Injection Topotecan Teva Topotecan Actavis Teva-topotecan
Indication	For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
Categories	Alkaloids Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Substrates Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 Enzyme Inhibitors Drugs that are Mainly Renally Excreted Enzyme Inhibitors Immunosuppressive Agents MATE 1 Inhibitors MATE 1 Substrates MATE 1 Substrates with a Narrow Therapeutic Index MATE 2 Substrates MATE 2 Substrates with a Narrow Therapeutic Index MATE inhibitors MATE substrates Myelosuppressive Agents Narrow Therapeutic Index Drugs P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Topoisomerase I Inhibitors Topoisomerase Inhibitors
ATC-Code	L01XX17
CAS number	123948-87-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
DNA topoisomerase 1	MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHS...	unknown	inhibitor
DNA topoisomerase I, mitochondrial	MRVVRLLRLRAALTLLGEVPRRPASRGVPGSRRTQKGSGARWEKEKHEDG...	unknown	inhibitor
DNA	-	unknown	intercalation
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Multidrug and toxin extrusion protein 1	MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQL...	unknown	substrate,inhibitor
Multidrug and toxin extrusion protein 2	MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFM...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682